# Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

> **NCT00683410** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 3366 (actual)

## Conditions studied

- Vaccines, Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)

## Key facts

- **NCT ID:** NCT00683410
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 3366 (ACTUAL)
- **Last updated:** 2010-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683410, "Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00683410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*